EUVIMEDEUVIMED entdecken
Crossref

Respiratory Disorders Associated with Antibody–Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases

Victor Mirleau, Alex Hlavaty iD, Etienne-Marie Jutant iD, Florence Hennegrave, Kévin Bihan iD, Romane Freppel, Clément Cholle iD, Delphine Bourneau-Martin iD, Claire Lafay-Chebassier iD, Julien Mahé iD, Matthieu Bainaud iD, Marion Allouchery iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Victor Mirleau und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université de Poitiers, CHU de Poitiers, Pneumologie, Poitiers, France. Hauptthemen laut MEDLINE: Immunoconjugates, Lung Diseases, Interstitial, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates are proving to be highly effective in oncology, yet their real‐world respiratory safety profile remains largely unknown. This study sought to characterize drug‐linked respiratory disorders and identify safety signals. We performed a descriptive analysis with expert review of respiratory adverse drug reactions related to antibody–drug conjugates from the French pharmacovigilance database. We also conducted disproportionality analyses for interstitial lung disease, pulmonary arterial hypertension, and pleural disorder using VigiBase®. Among the 71 patients included in the descriptive study, 56 (78.9%) were women, and the median age was 60 years. Most (71.8%) were treated for breast cancer. Fifty‐nine patients (83.1%) developed antibody–drug conjugate‐related interstitial lung disease, primarily after trastuzumab deruxtecan. Nine patients (12.7%) developed pulmonary arterial hypertension and three (4.2%) contracted pleural disorders, mainly after trastuzumab emtansine. The median time to onset varied by clinical feature, with 1 month for pleural disorder, 4 months for interstitial lung disease, and 45 months for pulmonary arterial hypertension. The disproportionality analysis showed a significant signal for interstitial lung disease with brentuximab vedotin, polatuzumab vedotin, trastuzumab emtansine, and trastuzumab deruxtecan. Only trastuzumab emtansine had a significant signal for pulmonary arterial hypertension. All antibody–drug conjugates, except belantamab mafodotin and enfortumab vedotin, were associated with a significant signal for pleural disorders. Our study highlights the risk of interstitial lung disease with these drugs in real‐world settings and identified pulmonary arterial hypertension and pleural disorders as additional safety signals. Further research is needed to confirm these findings in population‐based studies and to identify antibody–drug conjugates and patient‐related risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesLung Diseases, InterstitialAntineoplastic Agents, ImmunologicalHumansPharmacovigilanceFemaleMiddle AgedMaleFranceAgedDatabases, FactualAdultWorld Health OrganizationAdverse Drug Reaction Reporting SystemsAged, 80 and overTrastuzumabAdo-Trastuzumab Emtansine

Substanzen

ImmunoconjugatesTrastuzumabAntineoplastic Agents, ImmunologicalAdo-Trastuzumab Emtansine

Autor:innen und Institutionen

  • Université de Poitiers, CHU de Poitiers, Pneumologie, Poitiers, France.
  • Univ. Grenoble-Alpes, Pharmacovigilance Unit, Grenoble-Alpes University Hospital, Grenoble, France.
  • Univ. Grenoble-Alpes, INSERM CIC1406, CHU de Grenoble, Grenoble, France.
  • Univ. Grenoble-Alpes, HP2 Laboratory, INSERM U1300, Grenoble, France.
  • Pharmacology Department, APHP, GHU Sorbonne University, Regional Pharmacovigilance Center Pitié-Saint Antoine, Paris, France.
  • Centre Régional de Pharmacovigilance, CHU Dijon, Univ. Montpellier, Institut Desbrest d'Epidemiologie et de Sante Publique (IDESP), Montpellier, France.

ORCID-Profile: Alex Hlavaty, Etienne-Marie Jutant, Kévin Bihan, Clément Cholle, Delphine Bourneau-Martin, Claire Lafay-Chebassier, Julien Mahé, Matthieu Bainaud, Marion Allouchery

Zitieren

APA

Mirleau, V., Hlavaty, A., Jutant, E. M., Hennegrave, F., Bihan, K., Freppel, R., Cholle, C., Bourneau-Martin, D., Lafay-Chebassier, C., Mahé, J., Bainaud, M., & Allouchery, M. (2026). Respiratory Disorders Associated with Antibody–Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70119

Vancouver

Mirleau V, Hlavaty A, Jutant EM, Hennegrave F, Bihan K, Freppel R, et al. Respiratory Disorders Associated with Antibody–Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70119

BibTeX
@article{Mirleau2026,
  author = {Mirleau, Victor and Hlavaty, Alex and Jutant, Etienne-Marie and Hennegrave, Florence and Bihan, Kévin and Freppel, Romane and Cholle, Clément and Bourneau-Martin, Delphine and Lafay-Chebassier, Claire and Mahé, Julien and Bainaud, Matthieu and Allouchery, Marion},
  title = {Respiratory Disorders Associated with Antibody–Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70119}
}
Kostenlos starten →